Literature DB >> 3207892

Experiences with the Ommaya reservoir for prophylaxis and treatment of the central nervous system in adult acute myelocytic leukemia.

H Haaxma-Reiche1, S Daenen, R J Witteveen.   

Abstract

Intraventricular chemotherapy was administered to adult AML patients via an Ommaya reservoir. Twenty-eight patients received central nervous system (CNS) prophylaxis and seven patients were treated for meningeal leukemia (ML). A treatment course lasted at least 6 months. Asymptomatic ML developed in two patients (7%) of the prophylaxis group concomitantly with bone marrow relapse. One of these patients had not completed the standard course. CNS remission could be obtained in all evaluable patients with ML. The easy entrance to the cerebrospinal fluid (CSF) offers the advantage of frequent investigations of the CSF, early diagnosis and treatment of CNS relapses without radiotherapy, and caused little patient discomfort. CNS prophylaxis in this small study seemed to prolong first remission duration slightly. In M4 and M5 subtypes CNS prophylaxis can be valuable.

Entities:  

Mesh:

Year:  1988        PMID: 3207892     DOI: 10.1007/bf00320756

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  27 in total

1.  Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission.

Authors:  B A Peterson; R D Brunning; C D Bloomfield; D D Hurd; J A Gau; G T Peng; A I Goldman
Journal:  Am J Med       Date:  1987-09       Impact factor: 4.965

2.  6-Azauridine in combination chemotherapy of childhood acute myelocytic leukemia.

Authors:  T R Walters; R J Aur; K Hernandez; T Vietti; D Pinkel
Journal:  Cancer       Date:  1972-04       Impact factor: 6.860

3.  Factors that influence the appearance of central nervous system leukemia.

Authors:  S Pavlovsky; M Eppinger-Helft; F Sackmann Muriel
Journal:  Blood       Date:  1973-12       Impact factor: 22.113

4.  Absence of predictive parameters for CNS involvement in adult non-lymphocytic leukaemia at time of diagnosis.

Authors:  Y Shoenfeld; M Rothenberg; S Berliner; L A Gallant; D Garfinkel; M Shaklai; J Pinkhas
Journal:  Scand J Haematol       Date:  1982-04

5.  Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia.

Authors:  G V Dahl; J V Simone; H O Hustu; C Mason
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

6.  Natural history of central nervous system acute leukemia in adults.

Authors:  D J Stewart; M J Keating; K B McCredie; T L Smith; E Youness; S G Murphy; G P Bodey; E J Freireich
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

7.  The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A).

Authors:  A E Evans; E S Gilbert; R Zandstra
Journal:  Cancer       Date:  1970-08       Impact factor: 6.860

8.  Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.

Authors:  P H Wiernik; S C Schimpff; C A Schiffer; J L Lichtenfeld; J Aisner; M J O'Connell; C Fortner
Journal:  Cancer Treat Rep       Date:  1976-01

9.  Development of CNS leukaemia in acute myeloid leukaemia in childhood.

Authors:  H E Kay
Journal:  Arch Dis Child       Date:  1976-01       Impact factor: 3.791

10.  [Acute myelocytic leukemia in childhood: results of treatment from 1964 to 1979].

Authors:  H J Plüss; W H Hitzig
Journal:  Schweiz Med Wochenschr       Date:  1980-10-04
View more
  1 in total

Review 1.  Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.

Authors:  Gudrun Fleischhack; Ulrich Jaehde; Udo Bode
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.